

CBGA CBDA Capsules

King Of Hemp MME ID: Ingestible, Capsule



Sample: DIGP2207.0774.I.05135

Sample Date: 07/08/2022 Report Date: 07/11/2022

LOO

Terpene Test Results

CAS No.

METRC Sample:

Mass

Not Tested

Mass

Production Run #: 850010881539;

Potency Test Results

Analyte

Cannabinoid Test Results

digipathLabs

| 1 | | Mark 7 | | |
|---|----------------|----------------------|--|----|
| | | | | |
| | A COLUMN TO | SECTION AND ADDRESS. | | |
| | | - | | |
| | Ecology | | | 3 |
| | - | | | Ø. |
| | | | | |
| | 2.17 | | | |
| | | | | |
| | | 2010 | | |
| | - 10 | 1 | | |
| | 10000 | 10000 | A CONTRACTOR OF THE PARTY OF TH | |

1 Unit = 1 capsule, 0.3074g

0.069 mg/unit

Total Potential THC

0.069 Total THC/1 capsule THC/Unit

100.106 mg/unit

Total Potential CBD

100.106 Total CBD/1 capsule CBD/Unit

| Analyte | LOQ | Mass | Mass | |
|---------|--------|--|------------------------------|----|
| | % | mg/unit | % | |
| THCa | 0.0100 | 0.078 | 0.0255 | |
| Δ9-THC | 0.0100 | <loq< th=""><th><loq< th=""><th></th></loq<></th></loq<> | <loq< th=""><th></th></loq<> | |
| Δ8-THC | 0.0100 | <loq< th=""><th><loq< th=""><th></th></loq<></th></loq<> | <loq< th=""><th></th></loq<> | |
| THCV | 0.0100 | <loq< th=""><th><loq< th=""><th></th></loq<></th></loq<> | <loq< th=""><th></th></loq<> | |
| CBDa | 0.0100 | 111.589 | 36.3010 | |
| CBD | 0.0100 | 2.242 | 0.7295 | 1/ |
| CBDV | 0.0100 | 0.149 | 0.0485 | I |
| CBN | 0.0100 | <loq< th=""><th><loq< th=""><th></th></loq<></th></loq<> | <loq< th=""><th></th></loq<> | |
| CBGa | 0.0100 | 55.297 | 17.9885 | |
| CBG | 0.0100 | 11.624 | 3.7815 | |
| CBC | 0.0100 | 0.232 | 0.0755 | |
| Total | | 181.212 | 58.9500 | |

Total Potential THC = (THCa * 0.877) + d9-THC + d8-THC, Total Potential CBD = (CBDa * 0.877) + CBD, LOQ = Limit of Quantitation; NR = Not Reported; ND = Not Detected; Cannabinoids for flower and trim reported as received. Cannabinoids analyzed per Digipath Labs SOP-317 on an Agilent 1260 UPLC.

NR = Not Reported; ND = Not Detected; LOQ = Limit of Quantification. Terpenes analyzed per Digipath Labs SOP-333 on an Agilent FID-GCMS or Digipath Labs SOP-334 on an Agilent 7697A/7890B/5977A Headspace GC/MS.

CANNABINOIDS LABELING SUGGESTION PER NAC 453A.508

CBN/Unit

0.069 mg Total <LOQ mg CBN / THC / 1 capsule 1 capsule

THC/Unit

CBD/Unit 100.106 mg Total CBD / 1 capsule

Scan to View Results



Safety & Quality Tests

Visual Not Tested Moisture Content Not Tested Microbiological Not Tested Homogeneity Not Tested **Heavy Metals** Not Tested Residual Solvents Not Tested Mycotoxins Not Tested Pesticides Not Tested Water Activity Not Tested pH Not Tested

> I certify that this sample has been tested by DigiPath Labs. All results are reported on AS-IS basis.



Scientific Director

Accreditation #99721

All pass/fail limits are as specified in NCCR, NAC 453.A and DPBH Policies. Unless otherwise stated, all quality control samples performed within specifications previously established by the Laboratory. This product has been tested by Digipath Labs, Inc. using validated testing methodologies under a QMS as required by ISO-17025:2017 and Nevada state law. Sample collected per Digipath Labs' SOP-312. Values reported relate only to the product tested. Water activity tested at 250 C. Digipath Labs, Inc. makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein and treats all client communication and testing results as confidential. This Certificate shall not be reproduced without the written approval of Digipath Labs, Inc. Measurement Uncertainty values have been determined for all methods and analytes.